PDGFRβ PET imaging to detect cardiac fibrosis after heart attack or in HFpEF

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, cross-sectional and longitudinal imaging effort uses a microdose PET tracer ([68Ga]Ga-DOTA-Cys-ATH001) that targets PDGFRβ, a marker of pericyte-derived fibrogenic cells, together with myocardial perfusion PET and gadolinium MRI to map fibrosis-related signals. Four cohorts are enrolled: high-risk STEMI, low-risk STEMI, HFpEF, and healthy controls, with imaging performed on integrated PET/MRI or on separate PET/CT plus MRI systems. Imaging sessions include dynamic myocardial perfusion PET with 15O-H2O, dynamic and static PDGFRβ PET scans, and MRI sequences to measure extracellular volume in infarcted tissue. The goal is to characterize PDGFRβ expression patterns over time and across clinical groups without introducing therapeutic interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willing and able to give written informed consent for participation in the trial and able to comply with all trial procedures and requirements.
* Male or female participant aged 40 to 70 years, inclusive, at the screening visit.
* Women of childbearing potential must practice abstinence from heterosexual intercourse or must agree to use a highly effective method of contraception.

Cohort-specific inclusion criteria:

Cohort 1, STEMI high-risk patients:

* NT-proBNP \>500 pg/mL within 48 hrs after PCI
* Post-PCI Thrombolysis In Myocardial Infarction (TIMI) score \<3.
* No previous history of coronary artery disease or heart failure.

Cohort 2, STEMI low-risk patients

* NT-proBNP \<500 pg/mL within 48 hrs after PCI
* Post-PCI TIMI score 3.
* No previous history of coronary artery disease or heart failure.

Cohort 3 (HFpEF patients)

* Presence of signs and symptoms of HF
* Ejection Fraction ≥50%
* Elevated levels of natriuretic peptides (NT-proBNP≥125pg/mL)
* At least one of the following:
* Relevant structural heart disease (left ventricular hypertrophy or left atrial enlargement)
* Diastolic dysfunction

Cohort 4 (healthy participants)

* Individuals with no history of coronary disease or heart failure.
* Medically healthy participant without abnormal clinically significant medical history, physical findings, vital signs, ECG, and laboratory values at the time of the screening visit, as judged by the Investigator.

Exclusion Criteria:

* Any contraindication for MRI according to a standard checklist
* Having worked as a metal worker or welder.
* Contraindication for gadolinium-based contrast agents such as risk of nephrogenic systemic fibrosis (NSF) or allergy to gadolinium.
* Kidney dysfunction measured as estimated Glomerular filtration rate (eGFR)\<30 mL/min/1.73m2
* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial or influence the results or the participant's ability to participate in the trial.
* Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the screening visit.
* Any malignancy within the past 12 months before the screening visit, with the exception of successfully treated basal cell carcinoma of the skin or in situ prostate cancer under active surveillance, with no interventions scheduled during the period of trial participation.
* Any active gastrointestinal hemorrhage in the past six months.
* Acute or chronic disabling stroke.
* Aortic aneurysm or aortic dissection.
* Hypertensive crisis.
* Circulatory unstable condition in need for mechanical support.
* Any planned major surgery within the duration of the trial participation.
* Participants who are pregnant, currently breastfeeding, or intend to become pregnant during the course of the trial.
* Poor peripheral venous access, as judged by the Investigator.
* The participant has any laboratory abnormality or condition that, in the Investigator's opinion, could adversely affect the safety of the participant or impair the assessment of trial results.
* The participant is using any prohibited concomitant medications as described in the protocol, at the discretion of the Investigator.
* The Investigator considers the participant unlikely to comply with trial procedures, restrictions, and requirements.

Additional exclusion criteria for all participants (cohorts 1,2 and 4):

* History of coronary artery disease or heart failure.

Where it's running

• Uppsala University Hospital
  Uppsala, Sweden Recruiting

Study contacts

• Principal investigator: Karl-Henrik Grinnemo, MD, PhD — Uppsala University Hospital
• Study coordinator: Karl-Henrik Grinnemo, MD, PhD
• Email: karl-henrik.grinnemo@uu.se
• Phone: +46186110000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reducing slow-flow and no-reflow during STEMI with a high-dose intracoronary adenosine protocol

  In STEMI patients undergoing primary PCI, this trial tests whether giving a high-dose intracoronary adenosine before balloon or stent inflation can prevent slow-flow or no-reflow.

  Recruiting at 2 sites Punjab Institute of Cardology · Lahore, Punjab Province and 1 other locations · NCT07898696

• Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF

  This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.

  Recruiting London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London, Ontario · NCT07893821

• Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease

  This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.

  Recruiting Odense University Hospital · Svendborg · NCT07878325

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• Resmetirom for MASH with HFpEF in adults

  This study tests whether resmetirom can be given safely and show liver-related effects in adults with MASH and heart failure with preserved ejection fraction over 24 weeks.

  Recruiting at 5 sites Phase 1 Madrigal Pharmaceuticals, Inc. · Peoria, Arizona and 4 other locations · NCT07830758

• Drug-coated balloons vs drug-eluting stents for immediate slow-flow/no-reflow in STEMI with high thrombus

  This study tests whether using a drug-coated balloon instead of a drug-eluting stent during PCI helps reduce immediate slow-flow or no-reflow in STEMI patients with high thrombus burden.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07806370

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.